Summary
The Corona Virus Disease (COVID-19) pandemic has increased mortality in countries worldwide. To evaluate the impact of the pandemic on mortality, excess mortality has been suggested rather than reported COVID-19 deaths. Excess mortality, however, requires estimation of mortality under non-pandemic conditions. Although many methods exist to forecast mortality, they are either complex to apply, require many sources of information, ignore serial correlation, and/or are influenced by historical excess mortality. We propose a linear mixed model that is easy to apply, requires only historical mortality data, allows for serial correlation, and down-weighs the influence of historical excess mortality. Appropriateness of the linear mixed model is evaluated with fit statistics and forecasting accuracy measures for Belgium and the Netherlands. Unlike the commonly used 5-year weekly average, the linear mixed model is forecasting the subject-specific mortality, and as a result improves the estimation of excess mortality for Belgium and the Netherlands.
Competing Interest Statement
(1) GM acts as advisor and member of International Data Monitoring Committees for several biopharmaceutical clinical trials, including for a COVID-19 vaccination trial of J and J; he receives research funding from GSK; (2) none of the other authors has anything to disclose.
Funding Statement
CF and NH acknowledge funding from the Epipose project from the European Union's SC1-PHE-CORONAVIRUS-2020 programme, project number 101003688.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Not applicable
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data is openly available
